A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

By sjmartinez • April 8, 2024

Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Trukhin D, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Kohlmann M, Lowery C, Mann H, Peters S, Mok TS, Johnson ML. A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study. Clin Lung Cancer. 2024 Mar 15:S1525-7304(24)00038-X. doi: 10.1016/j.cllc.2024.03.003. Epub ahead of print. PMID: 38584069.

Tags: Clinical Trial, Cytotoxic T-lymphocyte-associated antigen 4, Hematology/Oncology, immune checkpoint inhibitor, immunotherapy, Programmed cell death ligand-1, Publications

Related Posts

A Pilot Test of an AI Voice-Driven Simulation With Feedback for Medical Students to Practice Discussing Diagnostic Mammogram Results With Patients

Comulada WS, Ganz PA, Huang YM, Weisman D, Sugarman A, Lee D, Shah S, Gelberg L. A Pilot Test of an AI Voice-Driven Simulation With[...]

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose[...]

Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy

Wang Y, Guan Y, Abbas AR, Sano Y, Jain S, Lu S, Hamidi H, Koeppen H, Azuma Y, Kayukawa Y, Shinozuka J, Pochiraju A, Webster[...]